Here's Why Select Medical (SEM) is a Strong Value Stock

Zacks Style Scores (Value, Growth, Momentum), rated A-F, complement the Zacks Rank by helping investors identify stocks with the highest probability of outperformance, particularly those with a Zacks Rank #1 or #2 and A/B Style Scores. Select Medical (SEM), a healthcare provider, is presented as a strong value opportunity, despite its Zacks Rank #3 (Hold), due to its "A" VGM Score and "A" Value Style Score, underpinned by an attractive forward P/E of 11.05, recent upward earnings estimate revisions for fiscal 2025 to $1.17 per share, and an average earnings surprise of +11.4%.

Analysis

Select Medical (SEM) is highlighted as a compelling value proposition, primarily due to its strong ratings within the Zacks Style Score system, despite a neutral Zacks Rank of #3 (Hold). The company's key appeal stems from its 'A' grade for both its Value Style Score and its aggregate VGM Score. This is quantitatively supported by an attractive forward P/E ratio of 11.05, suggesting a potential undervaluation relative to future earnings. While the stock's 'Hold' rating indicates a lack of significant recent upward earnings revisions across the board, there are nascent positive signs; one analyst has revised fiscal 2025 earnings estimates higher in the last 60 days, nudging the consensus estimate up by $0.02 to $1.17 per share. Furthermore, SEM has a consistent track record of outperformance, historically delivering an average earnings surprise of +11.4%, which may appeal to investors looking for operational stability.

Key Decisions for Investors

• Value-oriented investors should consider SEM's 'A' Value Score and forward P/E of 11.05 as a strong signal of a potentially undervalued security, warranting a place on their watchlist.
• Investors should weigh the promising value metrics against the neutral Zacks #3 (Hold) rank, which indicates that broad-based upward earnings estimate revisions, a key catalyst for price appreciation, are not yet present.
• Given the company's history of beating earnings expectations by an average of 11.4%, it may be prudent to monitor future earnings reports closely for continued outperformance that could trigger further analyst upgrades.
• The stock appears most suitable for patient investors who are comfortable with the current 'Hold' consensus but see potential for a future re-rating based on its strong underlying value characteristics and consistent operational execution.